Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045266 · ClinicalTrials.gov registry record · Phase 1
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00045266 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals.
The verdict
NCT00045266, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.
Interventions
- BIOLOGICAL ziv-aflibercept
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045266
The ClinicalTrials.gov registry entry for NCT00045266 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ziv-aflibercept is the first listed.
NCT00045266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045266 about?
NCT00045266 is a clinical study titled "VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma". RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.
What is the current status of trial NCT00045266?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-04.
What interventions are being tested in trial NCT00045266?
The interventions under investigation include: ziv-aflibercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00045266?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.